White matter lesions in Fabry disease before and after enzyme replacement therapy: a 2-year follow-up.
OBJECTIVE
To report the clinical and neuroimaging, central nervous system (CNS) findings of patients with Fabry disease (FD) during 24 months of enzyme replacement therapy (ERT) with agalsidase-alpha.


METHODS
Eight patients were included. Six completed 24 months of ERT. Clinical and magnetic resonance imaging (MRI) data were obtained at 0, 12 and 24 months of ERT. White matter lesions (WML) were evaluated as well as their relation to age, symptoms and neurological examination (CNS score).


RESULTS
MRI was stable in 3 patients. WML and CNS score worsened in one patient, fluctuated in another, and improved in the sixth patient. In the whole series, there were 15 WML at baseline, and 19 at the 24th month. In two years, 4 lesions disappeared, whereas 8 appeared.


CONCLUSIONS
A widespread pattern of silent WML in FD was seen. In two years, some WML appeared, and some disappeared. If these phenomena were related to the natural history, remains to be demonstrated.
Jardim
Laura B
LB
Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.
Aesse
Flávio
F
Vedolin
Leonardo M
LM
Pitta-Pinheiro
Cláudio
C
Marconato
João
J
Burin
Maira G
MG
Cecchin
Cláudia
C
Netto
Cristina B O
CB
Matte
Ursula S
US
Pereira
Fernanda
F
Kalakun
Luciane
L
Giugliani
Roberto
R
D000328:Adult; D001921:Brain / Q000201:enzymology / Q000473:pathology*; D000795:Fabry Disease / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination; D016896:Treatment Outcome; D000519:alpha-Galactosidase / Q000008:administration & dosage*
D000519:alpha-Galactosidase